EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mir221/222 drive synovial hyperplasia and arthritis by targeting cell cycle inhibitors and chromatin remodeling components

Fani Roumelioti iD, Christos Tzaferis, Dimitris Konstantopoulos, Dimitra Papadopoulou, Alejandro Prados, Maria Sakkou, Anastasios Liakos, Panagiotis Chouvardas, Theodore Meletakos, Yiannis Pandis, Niki Karagianni, Maria C Denis und 3 weitere

eLife · 05.09.2024 · 13

DOI: 10.7554/elife.84698 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, online erschienen am 05.09.2024. Verfasst von Fani Roumelioti und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Bioinnovation, Biomedical Sciences Research Centre (BSRC) "Alexander Fleming", Vari, Greece. Hauptthemen laut MEDLINE: MicroRNAs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative, Operational Programme "Competitiveness, Entrepreneurship and Innovation", NSRF 2014-2020, ERDF, EU/Greece, Regional Operational Programme "ATTICA" (NSRF 2021-2027), ERDF, Greece/EU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

miRNAs constitute fine-tuners of gene expression and are implicated in a variety of diseases spanning from inflammation to cancer. miRNA expression is deregulated in rheumatoid arthritis (RA); however, their specific role in key arthritogenic cells such as the synovial fibroblast (SF) remains elusive. Previous studies have shown that Mir221/222 expression is upregulated in RA SFs. Here, we demonstrate that TNF and IL-1β but not IFN-γ activated Mir221 /222 gene expression in murine SFs. SF-specific overexpression of Mir221/222 in huTNFtg mice led to further expansion of SFs and disease exacerbation, while its total ablation led to reduced SF expansion and attenuated disease. Mir221/222 overexpression altered the SF transcriptional profile igniting pathways involved in cell cycle and ECM (extracellular matrix) regulation. Validation of targets of Mir221/222 revealed cell cycle inhibitors Cdkn1b and Cdkn1c , as well as the epigenetic regulator Smarca1 . Single-cell ATAC-seq data analysis revealed increased Mir221 /222 gene activity in pathogenic SF subclusters and transcriptional regulation by Rela , Relb , Junb , Bach1 , and Nfe2l2 . Our results establish an SF-specific pathogenic role of Mir221/222 in arthritis and suggest that its therapeutic targeting in specific subpopulations could lead to novel fibroblast-targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsAnimalsMiceArthritis, RheumatoidChromatin Assembly and DisassemblyFibroblastsGene Expression RegulationSynovial Membrane

Stichwörter der Autor:innen

cell proliferationexpansionimmunologyinflammationmiRNAsmouserheumatoid arthritissc-ATAC seqsynovial fibroblasts

Substanzen

MicroRNAsMIRN221 microRNA, mouseMIRN222 microRNA, mouse

Autor:innen und Institutionen

  • Institute for Bioinnovation, Biomedical Sciences Research Centre (BSRC) "Alexander Fleming", Vari, Greece.
  • Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Center of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, Greece.
  • Institute for Fundamental Biomedical Research, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece.
  • Biomedcode Hellas SA, Vari, Greece.

ORCID-Profile: Fani Roumelioti, Maria Armaka, George Kollias

Förderung

  • Innovative Medicines Initiative
  • Operational Programme "Competitiveness, Entrepreneurship and Innovation", NSRF 2014-2020, ERDF, EU/Greece
  • Regional Operational Programme "ATTICA" (NSRF 2021-2027), ERDF, Greece/EU
  • Hellenic Foundation for Research and Innovation
  • HORIZON EUROPE European Research Council

Zitieren

APA

Roumelioti, F., Tzaferis, C., Konstantopoulos, D., Papadopoulou, D., Prados, A., Sakkou, M., Liakos, A., Chouvardas, P., Meletakos, T., Pandis, Y., Karagianni, N., Denis, M. C., Fousteri, M., Armaka, M., & Kollias, G. (2024). Mir221/222 drive synovial hyperplasia and arthritis by targeting cell cycle inhibitors and chromatin remodeling components. eLife, 13. https://doi.org/10.7554/elife.84698

Vancouver

Roumelioti F, Tzaferis C, Konstantopoulos D, Papadopoulou D, Prados A, Sakkou M, et al. Mir221/222 drive synovial hyperplasia and arthritis by targeting cell cycle inhibitors and chromatin remodeling components. eLife. 2024;13. doi:10.7554/elife.84698

BibTeX
@article{Roumelioti2024,
  author = {Roumelioti, Fani and Tzaferis, Christos and Konstantopoulos, Dimitris and Papadopoulou, Dimitra and Prados, Alejandro and Sakkou, Maria and Liakos, Anastasios and Chouvardas, Panagiotis and Meletakos, Theodore and Pandis, Yiannis and Karagianni, Niki and Denis, Maria C and Fousteri, Maria and Armaka, Maria and Kollias, George},
  title = {Mir221/222 drive synovial hyperplasia and arthritis by targeting cell cycle inhibitors and chromatin remodeling components},
  journal = {eLife},
  year = {2024},
  volume = {13},
  doi = {10.7554/elife.84698}
}
Kostenlos starten →